Leos Fuksa
Overview
Explore the profile of Leos Fuksa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
137
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jakubowski S, Kawalec P, Holko P, Kowalska-Bobko I, Kamusheva M, Petrova G, et al.
Front Pharmacol
. 2024 Mar;
15:1369178.
PMID: 38523639
The aim of this study was to characterize the reimbursement policy for orphan drugs (ODs) in Central and Eastern European (CEE) countries in relation to the availability and impact of...
2.
Inotai A, Csanadi M, Petrova G, Dimitrova M, Bochenek T, Tesar T, et al.
Biomed Res Int
. 2018 Mar;
2018:9597362.
PMID: 29546072
This policy research aims to map patient access barriers to biologic treatments, to explore how increased uptake of biosimilars may lower these hurdles and to identify factors limiting the increased...
3.
Vytrisalova M, Touskova T, Fuksa L, Karascak R, Palicka V, Byma S, et al.
Front Pharmacol
. 2017 May;
8:258.
PMID: 28553228
General practitioners (GPs) are key participants in osteoporosis (OP) management. The aim was to evaluate their adherence to lege artis management of the disease, potential barriers, and to discuss differences...
4.
Touskova T, Vytrisalova M, Palicka V, Hendrychova T, Chen Y, Fuksa L
Front Pharmacol
. 2016 Oct;
7:339.
PMID: 27746732
Osteoporosis is a chronic disease and adherence can fluctuate over time. Therefore, longer observation is necessary to investigate the stability of patients' adherence. The study aim was to compare the...
5.
Touskova T, Vytrisalova M, Palicka V, Hendrychova T, Fuksa L, Holcova R, et al.
Patient Prefer Adherence
. 2016 Jan;
9:1771-9.
PMID: 26719680
Purpose: All current recommendations include calcium and vitamin D (Ca-D) as an integrated part of osteoporosis treatment. The purpose of this pilot study was to analyze compliance with a fixed...
6.
Fuksa L, Vytrisalova M
Curr Med Res Opin
. 2015 Jun;
31(9):1645-53.
PMID: 26121231
Objectives: The objective was to analyze adherence and current trends in utilization and prescription practice patterns of the anti-RANKL monoclonal antibody denosumab in the treatment of postmenopausal osteoporosis (OP). Methods:...
7.
Fuksa L, Vocelka M, Vytrisalova M
Health Policy
. 2015 May;
119(9):1255-64.
PMID: 25929214
Objectives: In the Czech Republic (CZ) extensive price regulation and prescribing conditions are common instruments often employed with new drugs. Since the introduction of statins onto the market in 1990s...
8.
Muchova L, Vanova K, Suk J, Micuda S, Dolezelova E, Fuksa L, et al.
J Cell Mol Med
. 2015 Feb;
19(5):924-33.
PMID: 25683492
Estrogen-induced cholestasis is characterized by impaired hepatic uptake and biliary bile acids secretion because of changes in hepatocyte transporter expression. The induction of heme oxygenase-1 (HMOX1), the inducible isozyme in...
9.
Fuksa L, Vytrisalova M, Hendrychova T, Hrubesova I, Vlcek J, Palicka V
Acta Pol Pharm
. 2014 Oct;
71(2):329-35.
PMID: 25272654
Anti-osteoporosis drugs with osteoanabolic (teriparatide, intact parathormone) and dual (strontium ranelate) mechanism of action are currently available for the treatment of postmenopausal, glucocorticoid induced or male osteoporosis in the Czech...
10.
Kolouchova G, Brcakova E, Hirsova P, Cermanova J, Fuksa L, Mokry J, et al.
Life Sci
. 2011 Sep;
89(19-20):717-24.
PMID: 21925516
Aims: To evaluate iron biochemistry and contributing liver mechanisms during obstructive cholestasis and pravastatin treatment in rats. Main Methods: A rat model of cholestasis induced by bile duct ligation (BDL)...